Memorializing Governor Kathy Hochul to proclaim May 2025, as Cystic Fibrosis Awareness Month in the State of New York
Summary
This resolution memorializes Governor Kathy Hochul to proclaim May 2025 as Cystic Fibrosis Awareness Month in New York State. It is a ceremonial measure that recognizes cystic fibrosis as a serious genetic disease and highlights the work of the Cystic Fibrosis Foundation, the importance of research, and the need for continued public awareness.
The resolution describes cystic fibrosis as a condition that affects the lungs and digestive system, notes the number of people living with the disease in New York and nationwide, and emphasizes the role of early diagnosis, infant screening, daily treatment, and access to innovative therapies. It also points to the presence of specialized treatment centers in New York and the importance of improving outcomes and quality of life for people with CF.
Impact
The bill does not amend the Public Health Law or create new regulatory requirements; instead, it urges the Governor to issue a proclamation designating May 2025 as Cystic Fibrosis Awareness Month. Its practical effect is symbolic and educational, aimed at increasing awareness of cystic fibrosis, encouraging support for research and treatment, and drawing attention to affected patients, families, and care providers in New York.
Sentiment
The overall sentiment is strongly supportive and noncontroversial. The resolution uses celebratory and compassionate language, reflecting the Legislature’s customary practice of recognizing awareness months for serious illnesses. No votes, committee debate, or recorded opposition are provided, and the text presents the measure as a consensus-driven awareness effort.
Contention
No specific points of contention are identified in the available materials. Because the resolution is commemorative rather than substantive, there is no evidence of disagreement over policy, funding, or regulatory changes. The only implied emphasis is on the need for greater public awareness and access to innovative treatments, but no opposing viewpoint is recorded.